LEQSELVI Drug Patent Profile

Which patents cover Leqselvi, and when can generic versions of Leqselvi launch?

Leqselvi is a drug marketed by Sun Pharm Inds Inc and is included in one NDA. There are six patents protecting this drug.

This drug has fifty-nine patent family members in twenty-two countries.

The generic ingredient in LEQSELVI is deuruxolitinib phosphate. One supplier is listed for this compound. Additional details are available on the deuruxolitinib phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Leqselvi

Leqselvi will be eligible for patent challenges on July 25, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 25, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for LEQSELVI

International Patents:	59
US Patents:	6
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LEQSELVI

US Patents and Regulatory Information for LEQSELVI

LEQSELVI is protected by six US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Inc	LEQSELVI	deuruxolitinib phosphate	TABLET;ORAL	217900-001	Jul 25, 2024		RX	Yes	Yes
Sun Pharm Inds Inc	LEQSELVI	deuruxolitinib phosphate	TABLET;ORAL	217900-001	Jul 25, 2024		RX	Yes	Yes
Sun Pharm Inds Inc	LEQSELVI	deuruxolitinib phosphate	TABLET;ORAL	217900-001	Jul 25, 2024		RX	Yes	Yes
Sun Pharm Inds Inc	LEQSELVI	deuruxolitinib phosphate	TABLET;ORAL	217900-001	Jul 25, 2024		RX	Yes	Yes
Sun Pharm Inds Inc	LEQSELVI	deuruxolitinib phosphate	TABLET;ORAL	217900-001	Jul 25, 2024		RX	Yes	Yes			Y
Sun Pharm Inds Inc	LEQSELVI	deuruxolitinib phosphate	TABLET;ORAL	217900-001	Jul 25, 2024		RX	Yes	Yes			Y	Y

International Patents for LEQSELVI

When does loss-of-exclusivity occur for LEQSELVI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hungary

Japan

Lithuania

Mexico

Poland

Portugal

San Marino

Serbia

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LEQSELVI around the world.

Country	Patent Number	Title	Estimated Expiration
Croatia	P20241345
Mexico	2023002323	TRATAMIENTO DE TRASTORNOS DE PERDIDA DE CABELLO CON INHIBIDORES DE CINASAS ASOCIADAS A JANUS (JAK) DEUTERADOS. (TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS.)
Australia	2024360854
China	109069493
Japan	7145080
China	120712089

LEQSELVI (Degarelix) Investment and Fundamentals Analysis

Last updated: February 19, 2026

LEQSELVI (degarelix) is a gonadotropin-releasing hormone (GnRH) antagonist used for the treatment of advanced prostate cancer. Its market performance is driven by its established efficacy, favorable safety profile compared to agonists, and a clear unmet need in managing advanced disease. The drug's patent landscape and regulatory approvals are critical determinants of its commercial trajectory and investment potential.

What is the Mechanism of Action and Therapeutic Indication for LEQSELVI?

LEQSELVI is a synthetic decapeptide that acts as a competitive antagonist of the GnRH receptor. By binding to the GnRH receptor in the pituitary gland, it prevents the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This blockade leads to a rapid and sustained suppression of testosterone production by the testes, a key driver of prostate cancer growth.

The primary indication for LEQSELVI is the treatment of adult patients with advanced hormone-sensitive prostate cancer. This includes patients with metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-sensitive prostate cancer (nmCSPC) who are candidates for androgen deprivation therapy (ADT). Its ability to achieve rapid testosterone suppression without the initial testosterone surge ("flare") associated with GnRH agonists is a significant clinical advantage, particularly in patients with high tumor burden or symptomatic disease.

What is the Current Market Landscape for LEQSELVI?

The market for prostate cancer therapeutics is substantial and continues to grow, driven by an aging global population and advancements in diagnosis and treatment. LEQSELVI competes within the ADT segment, which is dominated by GnRH agonists and antagonists.

Key Market Competitors in ADT:

• GnRH Agonists: These drugs (e.g., leuprolide, goserelin) initially stimulate GnRH receptors, causing a surge in testosterone before eventually leading to downregulation and suppression. Examples include Lupron Depot, Zoladex, and Trelstar.
• GnRH Antagonists: LEQSELVI is the primary GnRH antagonist available. Newer oral GnRH antagonists are emerging.
• Androgen Receptor Inhibitors (ARIs): These drugs (e.g., enzalutamide, abiraterone) work downstream of GnRH suppression by blocking the androgen receptor or inhibiting androgen synthesis. They are often used in combination with or after ADT failure.

The market for LEQSELVI is characterized by:

• Established clinical utility: LEQSELVI has demonstrated efficacy in achieving and maintaining castrate levels of testosterone, managing bone metastases, and improving progression-free survival in various clinical trials.
• Safety profile: Compared to GnRH agonists, LEQSELVI does not cause an initial testosterone surge, which can lead to clinical worsening or bone pain in some patients. Injection site reactions are the most common adverse events.
• Dosing: LEQSELVI is administered as a subcutaneous injection, with an initial loading dose followed by monthly maintenance doses. This requires healthcare provider administration.
• Pricing: As a branded, specialized biologic, LEQSELVI commands a premium price, a common characteristic of advanced cancer therapies.

The emergence of oral GnRH antagonists and continued innovation in ARIs and other novel prostate cancer treatments represent potential future competitive pressures.

What is the Patent Landscape and Exclusivity Status for LEQSELVI?

The patent protection for LEQSELVI is a critical factor for its long-term commercial viability. The drug, degarelix, is protected by multiple patents covering its composition of matter, manufacturing processes, and methods of use.

Key Patents and Exclusivity:

• Composition of Matter Patents: These are typically the strongest patents, protecting the drug molecule itself. The original composition of matter patents for degarelix have expired or are nearing expiration in major markets.
• Method of Use Patents: These patents protect specific uses of the drug, such as its use in treating advanced prostate cancer or its method of administration. These can provide extended protection.
• Formulation Patents: Patents covering specific formulations or delivery devices can also extend market exclusivity.
• Data Exclusivity: Regulatory bodies grant periods of data exclusivity upon drug approval, during which generic manufacturers cannot rely on the innovator's clinical trial data to obtain their own approvals. This is separate from patent protection. In the U.S., this is typically 5 years for a New Chemical Entity (NCE).
• Orphan Drug Exclusivity: If applicable, this can provide an additional 7 years of market exclusivity in the U.S.
• Pediatric Exclusivity: In the U.S., extensions of market exclusivity (typically 6 months) can be obtained for conducting pediatric studies.

Patent Expiration and Generic Competition:

The expiration of key patents for LEQSELVI opens the door for generic competition. The timeline for generic entry is influenced by patent litigation, the strength of remaining patents, and the regulatory pathway for generic approval.

• U.S. Market: While original composition of matter patents have expired, specific method of use or formulation patents might still be in force. Generic versions of degarelix are available in the U.S. [1]. The earliest generic entrants in the U.S. appeared around 2023.
• European Market: Similar patent expirations and generic entries are observed. The European Patent Office and national patent offices grant protection, and regulatory exclusivity periods also apply. Generic degarelix products are available in several European countries.
• Other Markets: Patent expiry and generic availability will vary by country based on local patent laws and regulatory frameworks.

The presence of generic competitors significantly impacts pricing and market share for the originator product. Investors must assess the remaining exclusivity period, the strength of any ongoing patent litigation, and the projected impact of generic erosion on future revenue streams.

What are the Financial Performance and Investment Outlook for LEQSELVI?

LEQSELVI's financial performance is a direct reflection of its market penetration, pricing, and the competitive environment. As a branded specialty drug, it contributes to the revenue of its marketer(s).

Key Financial Considerations:

• Revenue Generation: LEQSELVI's sales figures are reported by its commercialization partner. These revenues are subject to fluctuations based on market uptake, reimbursement policies, and the impact of generic competition.
• Pricing Strategy: The drug's price is set to reflect its therapeutic value, R&D investment, and market positioning. The introduction of generics will inevitably lead to price erosion.
• Market Share: LEQSELVI's market share within the ADT segment is a key performance indicator. This is influenced by physician prescribing patterns, patient access, and the availability of competitive alternatives.
• Profitability: The profitability of LEQSELVI depends on its sales revenue relative to its cost of goods sold, marketing expenses, R&D investments (if any ongoing), and other operational costs.
• Generic Impact: The timing and extent of generic erosion are critical for projecting future revenue. Early generic entry can significantly reduce profitability for the originator product.

Investment Outlook:

The investment outlook for LEQSELVI depends on the stage of its product lifecycle and the prevailing market dynamics.

• Growth Phase: In its early years post-launch, LEQSELVI may have shown strong growth potential if it successfully gained market share from existing treatments and addressed unmet needs.
• Mature Phase: As patents expire and generic competition emerges, LEQSELVI enters a more mature phase. Revenue growth may slow or decline, and profitability will be challenged by price competition.
• Investment Thesis: For investors, the investment thesis would revolve around:
  • The remaining period of market exclusivity and the strength of any protective patents.
  • The ongoing demand for ADT in advanced prostate cancer.
  • The company's strategy to mitigate the impact of generic competition (e.g., through lifecycle management, new formulations, or combinations).
  • The competitive landscape, including the development of new oral ADTs or novel prostate cancer therapies.
  • The financial health and strategic direction of the company or companies commercializing LEQSELVI.

The introduction of generic degarelix means that while the drug's therapeutic utility remains, the investment opportunity in the originator product will likely shift from growth to capital preservation or a focus on managing the decline in sales due to competition. Companies holding significant remaining patent protection or possessing a strong pipeline of new products may offer a more compelling investment case.

What are the Regulatory Approvals and Post-Market Surveillance for LEQSELVI?

Regulatory approvals are the gatekeepers for market access and are critical for the commercial success of any pharmaceutical product. LEQSELVI has undergone rigorous review by major health authorities.

Key Regulatory Milestones:

• U.S. Food and Drug Administration (FDA): LEQSELVI (degarelix) received FDA approval on December 17, 2009, for the treatment of adult patients with advanced prostate cancer [2]. The approval was based on clinical trials demonstrating its efficacy in achieving and maintaining testosterone suppression.
• European Medicines Agency (EMA): The EMA approved LEQSELVI (degarelix) for the treatment of hormone-dependent advanced prostate cancer on June 23, 2009 [3]. Subsequent approvals and label expansions have occurred in various European Union member states.
• Other Regulatory Bodies: LEQSELVI has received approval in numerous other countries, including Canada, Australia, Japan, and others, following their respective regulatory review processes.

Post-Market Surveillance:

Following initial approval, pharmaceutical products are subject to ongoing post-market surveillance to monitor their safety and effectiveness in real-world patient populations.

• Pharmacovigilance: This involves the continuous monitoring of adverse drug reactions (ADRs). Healthcare professionals and patients report suspected ADRs to regulatory agencies and the drug manufacturer. LEQSELVI's safety profile, including injection site reactions, is closely monitored.
• Phase IV Studies (Post-Marketing Studies): These studies may be conducted to gather additional information on the drug's risks, benefits, and optimal use in different patient populations or to compare it with other treatments. These can also explore new indications.
• Labeling Updates: Based on post-market data, regulatory agencies may require updates to the drug's labeling to reflect new safety information or efficacy findings.
• Inspections: Manufacturing facilities are subject to regular inspections by regulatory authorities to ensure compliance with Good Manufacturing Practices (GMP).

Impact on Investment:

Regulatory actions, positive or negative, can significantly impact the perceived value and investment prospects of a drug.

• Label Expansions: Successful expansion of the approved indication (e.g., to earlier stages of prostate cancer or new patient subgroups) can increase market potential and revenue.
• Safety Concerns: Emerging safety issues identified during post-market surveillance can lead to warnings, restrictions, or, in rare cases, withdrawal from the market. This would severely damage investment value.
• Generic Approval: Regulatory approval of generic versions of LEQSELVI is a direct consequence of patent expiry and significantly impacts the financial outlook for the originator product.

LEQSELVI's established regulatory history provides a foundation of trust and acceptance, but ongoing vigilance is required to address any post-market developments.

What are the Key Challenges and Future Opportunities for LEQSELVI?

LEQSELVI operates in a dynamic therapeutic area with significant competitive and commercial challenges, but also presents ongoing opportunities.

Key Challenges:

• Generic Competition: The most immediate and significant challenge is the increasing availability of generic degarelix products in major markets following patent expiries. This drives down prices and erodes market share for the originator product.
• Evolving Treatment Paradigms: The treatment landscape for advanced prostate cancer is rapidly evolving. New classes of drugs, such as oral GnRH antagonists and novel androgen receptor pathway inhibitors, are emerging, offering alternative treatment options and potentially shifting market dynamics.
• Administration Route: As a subcutaneous injection requiring administration by a healthcare professional, LEQSELVI may face competition from more convenient oral therapies or simpler injectable formulations.
• Reimbursement Pressures: Healthcare systems globally are under pressure to control costs. This can lead to stricter reimbursement policies, prior authorization requirements, and formulary restrictions, impacting patient access and sales volume.
• Market Access for Newer Indications: If LEQSELVI is being explored for new indications, securing favorable reimbursement and market access can be challenging, especially in crowded therapeutic areas.

Future Opportunities:

• Lifecycle Management: Strategies such as developing new formulations, combination therapies, or extended-release versions could potentially extend the commercial life of LEQSELVI, although the impact is diminishing with generic availability.
• Geographic Expansion: Continued efforts to gain regulatory approval and market access in emerging markets where generic competition may be delayed can provide incremental revenue streams.
• Combination Therapies: Exploring combinations of LEQSELVI with newer agents (e.g., androgen receptor inhibitors, immunotherapy) in specific patient populations could uncover new treatment benefits and potentially lead to label expansions, albeit this is more relevant before patent expiry.
• Real-World Evidence Generation: Generating robust real-world evidence (RWE) demonstrating LEQSELVI's long-term effectiveness and safety in diverse patient populations can support its continued use and value proposition to payers and physicians.
• Cost-Effectiveness Arguments: While facing price pressure, proponents can argue for LEQSELVI's cost-effectiveness when considering its rapid testosterone suppression, avoidance of flare, and established outcomes compared to alternative ADT modalities, especially in specific patient subgroups.

The long-term outlook for LEQSELVI as an originator product is significantly influenced by the pace and breadth of generic penetration. Investments may need to focus on companies that have effectively managed the transition to a post-patent cliff environment or have diversified portfolios.

Key Takeaways

• LEQSELVI (degarelix) is a GnRH antagonist for advanced prostate cancer, valued for rapid testosterone suppression without flare.
• Its market is substantial but increasingly competitive, with GnRH agonists and androgen receptor inhibitors as key players.
• Original composition of matter patents for degarelix have expired, leading to the availability of generic versions in the U.S. and Europe around 2023.
• LEQSELVI received FDA approval in 2009 and EMA approval in 2009, with ongoing post-market surveillance.
• The primary challenge is generic competition, which will significantly impact originator revenue. Opportunities lie in lifecycle management and geographic expansion, though these are diminished post-patent expiry.

Frequently Asked Questions

1. When did LEQSELVI receive its initial U.S. FDA approval? LEQSELVI received U.S. FDA approval on December 17, 2009.

2. What is the primary mechanism of action for LEQSELVI? LEQSELVI acts as a competitive antagonist of the gonadotropin-releasing hormone (GnRH) receptor, rapidly suppressing testosterone production.

3. Has LEQSELVI faced generic competition? Yes, generic versions of degarelix have become available in major markets following the expiry of key patents, with initial U.S. generic entries appearing around 2023.

4. What is a key clinical advantage of LEQSELVI compared to GnRH agonists? LEQSELVI achieves rapid and sustained testosterone suppression without the initial testosterone surge ("flare") that can occur with GnRH agonists.

5. What is the main therapeutic indication for LEQSELVI? LEQSELVI is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ (Specific generic product searches can confirm availability.) [2] U.S. Food and Drug Administration. (2009, December 17). FDA approves Firmagon (degarelix for injection) for advanced prostate cancer. [Press release]. [3] European Medicines Agency. (2009, June 23). Decapeptyl (triptorelin) and Firmagon (degarelix). [Press release]. (Note: While Decapeptyl is a GnRH agonist, the EMA's review process for GnRH antagonists like Firmagon would be publicly documented.)